Delivra Health Brands Inc. reports developments for a health-and-wellness consumer packaged goods business built around Dream Water sleep-support products and LivRelief topical brands. Company news commonly covers product launches, e-commerce and retail channel performance, distributor relationships, and regional market expansion for its branded wellness portfolio.
Recurring updates also include financial results, management discussion of revenue trends, non-IFRS performance measures such as Adjusted EBITDA, and licensing or manufacturing arrangements for products such as LivRelief Infused topicals in Canada.
Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF), a leader in consumer packaged goods in the health and wellness sector, has announced its upcoming annual financial results report for the year ending June 30, 2024. The company will host a conference call on Tuesday, October 8, 2024, at 11:00 a.m. (EST) / 8:00 a.m. (PST) to discuss these results.
The conference call will feature Gord Davey, President and CEO, and Jack Tasse, CFO, who will conduct a Q&A session following management's prepared remarks. Interested parties can join the call by dialing 1-844-763-8274 (Canada/USA Toll Free) or +1-647-484-8814 (International Toll). Participants are advised to dial in 10 minutes before the scheduled start time.
A replay of the call will be available on the company's investor page by the end of the business day on October 8, 2024.
Delivra Health Brands (TSXV: DHB, OTCQB: DHBUF), a leader in the health and wellness sector, has announced the grant of 14,000,000 incentive stock options. This resolution, passed by the Board on May 28, 2024, allows directors, officers, and employees to purchase shares at $0.05 each. These options vest annually over three years and have a five-year term. The initiative aims to align the interests of the company's insiders with its long-term performance and growth strategies.
Delivra Health Brands reported a 36% YoY revenue growth, achieving $8,792K in net revenue for the nine months ending March 31, 2024. The quarterly revenue rose by 31% to $3,071K. The company's adjusted EBITDA improved to $845K from $9K YoY. Gross profit for the nine months was $4,566K, a 61% increase, with a gross margin of 52%, up from 44%. However, total expenses increased by 22% to $3,973K due to marketing initiatives. Quarterly gross profit was $1,540K with a 50% margin. Net loss was $702K for the nine months, compared to $178K last year. The loss per share stood at $0.003 basic and $0.002 diluted. Overall, Delivra Health shows strong revenue growth and improved profitability, despite higher expenses.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.